Author:
Shigefuku Ryuta,Takahashi Hideaki,Watanabe Tsunamasa,Hattori Nobuhiro,Ikeda Hiroki,Matsunaga Kotaro,Ehira Takuya,Suzuki Tatsuya,Matsumoto Nobuyuki,Okuse Chiaki,Iwasa Motoh,Nakagawa Hayato,Itoh Fumio,Suzuki Michihiro
Abstract
Abstract
Objectives
To identify patients suitable for endoscopic injection sclerotherapy (EIS) by evaluating their portal hemodynamics and liver function.
Methods
We selected 58 patients with esophagogastric varices (EGV) and liver cirrhosis (LC) related to either hepatitis C virus (C) (n = 19), hepatitis B virus (n = 2), alcohol (AL) (n = 20), C + AL (n = 6), non-alcoholic steatohepatitis (n = 6), others (n = 3), or non-LC (n = 2). All patients underwent EIS. We measured their portal venous tissue blood flow (PVTBF) and hepatic arterial tissue blood flow (HATBF) using xenon computed tomography before and after EIS. We classified them into increased group and decreased group according to the PVTBF to identify the predictors that contribute to PVTBF increase post-EIS.
Results
Low value of indocyanine green retention at 15 min (ICG-R15), the absence of paraesophageal veins, and low baseline PVTBF/HATBF (P/A) ratio predicted increased PVTBF in the multivariate logistic analysis (odds ratio (OR) 10.46, p = 0.0391; OR 12.45, p = 0.0088; OR 13.57, p = 0.0073). The protein synthetic ability improved 1 year post-EIS in increased group. Cox proportional hazards regression identified alcohol drinking (hazard ratio; 3.67, p = 0.0261) as an independent predictor of EGV recurrence.
Conclusions
Patients with low ICG-R15, low P/A ratio, and the absence of paraesophageal veins were probable predictors of PVTBF improvement post-EIS. In addition, the improvement of hepatic hemodynamics likely enhanced liver function following EIS.
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,General Medicine
Reference25 articles.
1. Dai C, Liu WX, Jiang M, Sun MJ. Endoscopic variceal ligation compared with endoscopic injection sclerotherapy for treatment of esophageal variceal hemorrhage: a meta-analysis. World J Gastroenterol. 2015;21(8):2534–41.
2. Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res Offl J Jpn Soc Hepatol. 2021;51(7):725–49.
3. Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol. 2021;56(7):593–619.
4. Murata K, Sugimoto K, Okuda K, Shimizu A, Takase K, Nakano T, et al. Long-term effect of prophylactic endoscopic injection sclerotherapy on liver function. Hepatogastroenterology. 1998;45(23):1726–30.
5. Sugimoto K, Shiraki K, Murata K, Ito T, Ohmori S, Sakai T, et al. The effect of endoscopic injection sclerotherapy on portal blood flow and liver function. Hepatogastroenterology. 2002;49(48):1587–90.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献